Controlling brain receptor pairings to reveal new drug effects
A novel system for controlling dimeric receptor composition to discover unique heterodimer pharmacology
Researchers are building a way to control how certain brain receptors pair up so new medicines can work better for people with brain disorders.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Rochester NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project ID | NIH-11357660 on NIH RePORTER |
What this research studies
From a patient perspective, the team is creating a tool that forces specific metabotropic glutamate receptors to form only the receptor pairs they choose so each pair can be tested by itself. They will use engineered receptors in cell-based assays and biochemical tests to see how different drugs act on those specific pairings. By comparing responses from single-type receptor pairs (homodimers) and mixed pairs (heterodimers), they will map which drug effects depend on receptor pairing. This mapping is intended to reveal why some drugs work in lab tests but not in complex brain settings and to guide design of more effective therapies.
Who could benefit from this research
Good fit: This project does not enroll patients, but its results could eventually inform future clinical trials for people with conditions linked to glutamate signaling, such as epilepsy, depression, or schizophrenia.
Not a fit: People whose conditions are unrelated to glutamate signaling or who need immediate clinical treatment are unlikely to benefit directly from this lab-focused research.
Why it matters
Potential benefit: If successful, this work could help scientists design drugs that target specific receptor pairings and lead to better treatments for neurological and psychiatric disorders.
How similar studies have performed: Previous work targeting mGluR receptors showed promise in preclinical models but did not translate reliably to patients, and focusing on heterodimer-specific pharmacology is a relatively new approach.
Where this research is happening
Rochester, United States
- University of Rochester — Rochester, United States (Active)
Researchers
- Principal investigator: Kammermeier, Paul J. — University of Rochester
- Study coordinator: Kammermeier, Paul J.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.